UK’s ‘Bold’ New Rare Disease Rulebook Has Novel Licensing Pathway And Provisional Approvals

 
• By Eliza Slawther
  
The MHRA’s proposals could be a major shake-up in rare disease drug regulation (Shutterstock)

More from Review Pathways

More from Cell & Gene Therapies